Clinical use of antibacterial mesh envelopes in cardiovascular electronic device implantations
David S Hirsh,1,2 Heather L Bloom1,2 1Department of Cardiovascular Medicine, School of Medicine, Emory University, Atlanta, GA, USA; 2Department of Cardiovascular Medicine, Atlanta Veterans Affairs Medical Center, Decatur, GA, USA Abstract: Cardiovascular implantable electronic device system infec...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2015
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/f9a4e3a83cd24688832471fe46695645 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | David S Hirsh,1,2 Heather L Bloom1,2 1Department of Cardiovascular Medicine, School of Medicine, Emory University, Atlanta, GA, USA; 2Department of Cardiovascular Medicine, Atlanta Veterans Affairs Medical Center, Decatur, GA, USA Abstract: Cardiovascular implantable electronic device system infection is a serious complication of cardiac device implantation and carries with it a risk of significant morbidity and mortality. In the last 15 years, expansions of indications for cardiac devices have resulted in much higher volumes of much sicker patients being implanted, carrying significant risk of infection. Coagulase (-) Staphylococcus and Staphylococcus aureus are responsible for the majority of these infections, and these organisms are increasingly resistant to methicillin. The Aigis™ envelop is a Food and Drug Administration–approved implantable mesh that is impregnated with antibiotics that can be placed in the surgical incision prior to closure. The antibiotics elute off the mesh for 7–10 days, providing in vivo surgical site coverage with rifampin and minocyclin. This paper reviews the three retrospective clinical trials published in peer-reviewed journals and the interim analysis of the two ongoing prospective trials that have been presented at international conferences. Overall consensus is that the Aigis™ offers significant risk reduction for cardiovascular implantable electronic device infection. We then give a comprehensive discussion of how to use the Aigis™ envelop in the clinical setting, comparing the manufacturer’s recommendations with our extensive clinical experience. Keywords: pacemaker, defibrillator, cardiac electronic implantable device, infection, Aigis™ |
|---|